title: Identification and characterization of the neutralization epitope(s) of the hepatitis E virus.
abstract: The neutralization epitope(s) of the hepatitis E virus (HEV) was studied by an in vitro neutralization assay using antibodies obtained by immunization of mice with 51 overlapping 30-mer synthetic peptides spanning the region 221-660 amino acids (aa) of the HEV open reading frame 2 encoded protein (pORF2) and 31 overlapping recombinant proteins of different sizes derived from the entire pORF2 of the HEV Burma strain. Antibodies against synthetic peptides and short recombinant proteins of approximately 100 aa did not neutralize HEV, suggesting the HEV neutralization epitope(s) is conformation-dependent. However, one recombinant protein of approximately 400 aa in length comprising the pORF2 sequence at position 274-660 aa as well as all truncated derivatives of this protein containing region 452-617 aa elicited antibodies, demonstrating HEV neutralizing activity. These findings establish for the first time that the minimal size fragment, designated pB166, that can efficiently model the neutralization epitope(s) is 166 aa in length and is located at position 452-617 aa of the HEV pORF2. Additionally, antibodies against pB166 were found to cross-neutralize three different HEV genotypes, suggesting that a common neutralization epitope(s) may exist within the different HEV genotypes. Thus, recombinant proteins constructed in this study may be considered as potential candidates for the development of an HEV subunit vaccine as well as for the development of highly sensitive and specific diagnostic tests.
authors.affiliation: Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
authors.forename: J
authors.initials: J
authors.lastname: Meng
authors.forename: X
authors.initials: X
authors.lastname: Dai
authors.forename: J C
authors.initials: JC
authors.lastname: Chang
authors.forename: E
authors.initials: E
authors.lastname: Lopareva
authors.forename: J
authors.initials: J
authors.lastname: Pillot
authors.forename: H A
authors.initials: HA
authors.lastname: Fields
authors.forename: Y E
authors.initials: YE
authors.lastname: Khudyakov
mesh_terms: D000914:Antibodies, Viral / Q000276:immunology; D002213:Capsid / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions; D018604:Epitope Mapping; D018985:Epitopes, B-Lymphocyte / Q000235:genetics / Q000276:immunology*; D005982:Glutathione Transferase / Q000235:genetics / Q000276:immunology; D016752:Hepatitis E virus / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests; D010455:Peptides / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D018985:Epitopes, B-Lymphocyte; C400971:ORF2 protein, Hepatitis E virus; D010455:Peptides; D011993:Recombinant Fusion Proteins; D014764:Viral Proteins; D005982:Glutathione Transferase